Abstract
Patients:Soft tissue sarcomas are uncommon malignancies with few therapeutic options for recurrent or metastatic disease.
Dolastatin-10 (Dol-10) is a pentapeptide anti-microtubule agent that binds to tubulin sites distinct from vinca alkaloids.
Based on the novel mechanism of action, limited activity of other anti-microtubular agents, and anti-neoplastic activity in
pre-clinical screening of Dol-10, this multi-institutional phase II study was conducted to determine the objective response
rate of Dol-10 in recurrent or metastatic soft tissue sarcomas that had not been treated with chemotherapy outside of the
adjuvant setting.Methods: Dol-10 was given intravenously at a dose of 400 μg/m